Persistent heterogeneity in diabetes technology reimbursement for children with type 1 diabetes: The SWEET perspective
Language English Country United States Media print-electronic
Document type Comparative Study, Journal Article
PubMed
30773756
DOI
10.1111/pedi.12833
Knihovny.cz E-resources
- Keywords
- children, diabetes technology, reimbursement, type 1 diabetes,
- MeSH
- Diabetes Mellitus, Type 1 blood drug therapy economics epidemiology MeSH
- Child MeSH
- Adult MeSH
- Hypoglycemic Agents administration & dosage economics MeSH
- Insulin administration & dosage economics MeSH
- Insulin Infusion Systems economics MeSH
- Infant MeSH
- Blood Glucose analysis MeSH
- Humans MeSH
- Longitudinal Studies MeSH
- Adolescent MeSH
- Young Adult MeSH
- Costs and Cost Analysis MeSH
- Infant, Newborn MeSH
- Cost of Illness MeSH
- Child, Preschool MeSH
- Blood Glucose Self-Monitoring economics instrumentation MeSH
- Insurance, Health, Reimbursement * economics statistics & numerical data trends MeSH
- Inventions economics statistics & numerical data trends MeSH
- Equipment and Supplies economics MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Infant MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Infant, Newborn MeSH
- Child, Preschool MeSH
- Publication type
- Journal Article MeSH
- Comparative Study MeSH
- Geographicals
- Europe epidemiology MeSH
- Names of Substances
- Hypoglycemic Agents MeSH
- Insulin MeSH
- Blood Glucose MeSH
BACKGROUND: Frequent use of modern diabetes technologies increases the chance for optimal type 1 diabetes (T1D) control. Limited reimbursement influences the access of patients with T1D to these modalities and could worsen their prognosis. We aimed to describe the situation of reimbursement for insulins, glucometers, insulin pumps (CSII) and continuous glucose monitoring (CGM) for children with T1D in European countries participating in the SWEET Project and to compare data from EU countries with data from our previous study in 2009. METHODS: The study was conducted between March 2017 and August 2017. First, we approached diabetes technology companies with a survey to map the reimbursement of insulins and diabetic devices. The data collected from these companies were then validated by members of the SWEET consortium. RESULTS: We collected data from 29 European countries, whereas all types of insulins are mostly fully covered, heterogeneity was observed regarding the reimbursement of strips for glucometers (from 90 strips/month to no limit). CSII is readily available in 20 of 29 countries. Seven countries reported significant quota issues or obstacles for CSII prescription, and two countries had no CSII reimbursement. CGM is at least partially reimbursed in 17 of 29 countries. The comparison with the 2009 study showed an increasing availability of CSII and CGM across the EU. CONCLUSIONS: Although innovative diabetes technology is available, a large proportion of children with T1D still do not benefit from it due to its limited reimbursement.
APDP Diabetes Portugal and Nova Medical School Lisbon Portugal
Department of Medical Psychology Hannover Medical School Hannover Germany
Department of Pediatrics Diabetes Center P and A Kyriakou Children's Hospital Athens Greece
Department of Pediatrics KLE University's Jawaharlal Nehru Medical College Belgaum Belgaum India
Department of Pediatrics Medical University of Warsaw Warsaw Poland
Department of Pediatrics Medical University Varna UMHAT Sv Marina Varna Bulgaria
Department of Pediatrics Motol University Hospital Prague Czech Republic
References provided by Crossref.org
